Veronica A. Campbell

Woomera Therapeutics — United States

Neuroscience · Life Sciences

39h-index4.3kcitations102works17.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(34), Cannabis and Cannabinoid Research(20), Ion channel regulation and function(15), Mesenchymal stem cell research(13), Neuroinflammation and Neurodegeneration Mechanisms(10)

Publications102 total

Developmental toxicology profile of the IRAK4 degrader KT-474
Toxicological Sciences·2025· 1 cited
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
Journal of Medicinal Chemistry·2024· 42 citedOpen Access
IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers
Journal of Investigative Dermatology·2024· 8 citedOpen Access
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Nature Medicine·2023· 98 citedOpen Access
Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders
Frontiers in Immunology·2023· 13 citedOpen Access
Selective IRAK4 degradation, not kinase inhibition, blocks TLR-activated NF-Kb and p38 Signaling leading to broad cytokine inhibition
The Journal of Immunology·2022· 4 cited
LB819 Multiple mediators of inflammation correlate with IRAK4 expression in the skin of Hidradenitis Suppurativa patients and are blocked by the IRAK4 protein degrader KT-474 in TLR-activated monocytes
Journal of Investigative Dermatology·2021
IRAK4 degradation abrogates cytokine release and improves disease endpoints in murine models of IL-33/36- as well as Th17-driven inflammation
The Journal of Immunology·2021
Phenotypic Motor Impulsivity is Dynamically Altered Following Oxycodone Self‐Administration in Male Rats
The FASEB Journal·2021
Abstract LB-088: A STAT3 selective targeted protein degrader decreases the immunesuppressive tumor microenvironment and drives antitumor activity in preclinical models
Cancer Research·2020
Abstract 5222: Degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broader activity with durable and complete regressions in MYD88 mutant lymphoma xenografts <i>in vivo</i>
Cancer Research·2020· 1 cited
588 Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa
Journal of Investigative Dermatology·2020· 1 cited
Abstract LB-272: KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition
Experimental and Molecular Therapeutics·2019
KYM‐001, A FIRST‐IN‐CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88‐MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION
Hematological Oncology·2019· 5 cited
Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma
Blood·2018· 3 cited
Trinity College Dublin Estates Strategy, November 2018
Arrow@dit (Dublin Institute of Technology)·2018
Isolation and characterization of canine, equine and feline mesenchymal stem cells in Uruguay.
2018
A Dialectical Behavioral Therapy Adaptation in Reducing Depression, Anxiety, and Self-Harm in Older Adults
World Academy of Science, Engineering and Technology, International Journal of Psychological and Behavioral Sciences·2017
Analysis of the Impact of CD200 on Phagocytosis
Molecular Neurobiology·2016· 41 cited
The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets·2016· 25 cited
page 1 of 6Next →

Frequent Co-authors

Aoife Gowran(11), Marina A. Lynch(9), Patrick J. Prendergast(7), Nicholas S. Berrow(7), Annette Dolphin(7), Marie P. Fogarty(6), Kieran Brickley(6), Janis Noonan(6), Eric J. Downer(6), Eric Farrell(5), Fergal J. O’Brien(5), Louise A. McMahon(4), Brian O’Connell(3), Yvonne M. Nolan(3), Barry Boland(3), Aedín M. Minogue(3), Riffat Tanveer(3), Jan Fischer(2), Stephen D. Thorpe(2), Conor T. Buckley(2)